LIFECORE BIOMEDICAL, INC. DE (LFCR): Nasdaq/NYSE listing notice — Lifecore receives Nasdaq delisting notice for failure to file FY 2023 10-K and Q1/Q2 10-Qs

LIFECORE BIOMEDICAL, INC. DE

Nasdaq initiated delisting process on Feb 13, 2024 due to non-compliance with Listing Rule 5250(c)(1).
Company has not filed Form 10-K for FY ended May 28, 2023 nor Q1 and Q2 10-Qs for 2023.
Company intends to appeal before a Nasdaq Hearing Panel by Feb 20, 2024; hearing automates 15-day stay.
Hearing typically scheduled 30-45 days after request; no assurance of further stay or compliance before hearing.
Delinquent filings relate to a previously disclosed restatement for FY 2021, 2022 and other interim periods.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

LIFECORE BIOMEDICAL, INC. DE received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

February 13, 2024, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company’s securities from Nasdaq as a result of the Company not being in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchang

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

LIFECORE BIOMEDICAL, INC. DE filing history →

Source: SEC EDGAR

accession 0001005286-24-000020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.